#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D.

Episode Summary

Executive Summary: This episode explains thyroid physiology in depth and challenges oversimplified clinical approaches. Dr. Antonio Bianco argues that T3 is the biologically active hormone, deiodinases create major tissue-specific variability not captured by TSH alone, and many patients on levothyroxine remain biochemically or clinically undertreated. The discussion covers diagnosis, assay limitations, autoimmune disease, and the case for combination or slow-release T3 therapy.

Main Topics: Thyroid hormone biology and deiodinases (Priority: 5/5): The episode builds a detailed model of thyroid hormone production, storage, conversion, and inactivation. T4 is described as a prohormone, while T3 is the active hormone generated locally by deiodinases. Reverse T3 and D3 are framed as inactive pathways that reduce thyroid action. TSH, free T4, and the limits of blood testing (Priority: 5/5): Bianco explains why TSH is useful but incomplete, especially because it reflects pituitary feedback and not necessarily tissue-level thyroid status. The conversation emphasizes that symptoms, tissue metabolism, and lab values can diverge. Fasting, illness, and adaptive thyroid changes (Priority: 4/5): Using fasting as an example, the speakers show how low insulin/leptin and reduced hepatic D1 shift thyroid metabolism toward lower T3 and higher reverse T3, reducing energy expenditure as an adaptive response. Hypothyroidism diagnosis and autoimmune thyroiditis (Priority: 5/5): Hashimoto's disease is presented as the most common cause of hypothyroidism, but the episode also covers central hypothyroidism, subclinical hypothyroidism, antibody testing, ultrasound findings, and confounders such as menopause and anemia. Treatment debate: levothyroxine, T3, desiccated thyroid, and compounding (Priority: 5/5): The episode contrasts standard levothyroxine monotherapy with combination therapy and desiccated thyroid extract. Bianco argues many patients do better on some T3 exposure, while immediate-release and compounded slow-release T3 have major practical and evidence limitations. Outcomes, risk, and underrecognized consequences (Priority: 4/5): Bianco argues hypothyroidism is not benign: he cites cardiometabolic risk, persistent hypothyroid liver physiology in animal studies, statin co-prescribing, and observational evidence suggesting lower mortality with combination therapy versus levothyroxine alone. Future research and improved therapeutics (Priority: 4/5): The episode closes with a call for better T3 assays, CLIA mass spectrometry, and true slow-release T3 products, which Bianco believes could improve care for patients who do not fully respond to current treatment.

Key Arguments: T3 is the biologically active thyroid hormone, and tissues often regulate local T3 availability independently of circulating blood levels. TSH is an important screening and feedback marker, but it does not fully represent tissue-level thyroid action or patient wellbeing. Reverse T3 reflects a major inactivation pathway and can rise during fasting or illness as part of adaptive energy conservation. Most extra-thyroidal T3 is produced by D2; D3 is the main inactivating enzyme and makes both T3 and T4 biologically unavailable. Symptoms alone cannot reliably diagnose hypothyroidism because they overlap with menopause, anemia, obesity, and other conditions. Hashimoto's thyroiditis is the most common cause of primary hypothyroidism, but 40% of hypothyroid patients may be antibody-negative or have other etiologies. Levothyroxine is convenient and standard, but it may not restore true euthyroidism in all tissues, especially the liver. Combination therapy or desiccated thyroid may help selected patients who remain symptomatic on T4 alone. Routine T3 and reverse T3 immunoassays are imperfect; mass spectrometry would be better for accurate T3 measurement. The field needs slow-release T3 formulations to better mimic physiologic secretion and reduce peaks and troughs. Observational data presented in the episode suggest higher mortality in hypothyroid patients overall and lower mortality in those receiving combination therapy versus levothyroxine alone. High iodine intake can provoke autoimmune thyroid disease or iodine-induced dysfunction, so more is not always better.

Data Points: T4 half-life: about 8 days - Used to contrast T4 with the shorter-lived active hormone T3 T3 half-life: about 12 hours - Explains why T3 has potent but brief effects Reverse T3 half-life: just a few hours - Illustrates rapid clearance and limited utility as an active hormone D2 affinity for T4 vs D1: about 1,000-fold higher - Bianco describes D2 as much more efficient than D1 Extra-thyroidal T3 production: about 80% from D2 and 20% from D1 - Estimated contribution to T3 made outside the thyroid gland T4/T3 distribution in thyroid secretion: about 80% T4 and 20% T3 - Used as the physiologic rationale for combination replacement Adult hypothyroidism prevalence: about 4% to 5% of adults; roughly 20 million patients in the U.S. - Epidemiologic estimate given by Bianco Hyperthyroidism prevalence: far fewer than hypothyroidism; described as thousands to a few hundred thousand - Contrasted with the much more common hypothyroid population Congenital hypothyroidism incidence: 1 in 2,500 to 3,000 live births - Given as one non-autoimmune cause of hypothyroidism TPO-positive in Hashimoto's: about 60% of hypothyroid patients - Explains why many hypothyroid patients can still be antibody-negative Women-to-men ratio for hypothyroidism: about 4:1 to 10:1 - Shows strong female predominance Iodine intake recommendation for adults: about 150 micrograms/day - Normal daily intake to support thyroid hormone synthesis Iodine intake recommendation in pregnancy: about 250 micrograms/day - Higher requirement due to increased thyroid demand Japan typical iodine intake: about 500 to 600 micrograms/day - Cited as an example of excess intake associated with more autoimmune thyroid disease Combination therapy mortality reduction: about 30% lower mortality versus levothyroxine alone - From an observational comparison discussed in the episode Hypothyroid mortality burden: 2.5-fold greater mortality in levothyroxine-treated hypothyroid patients vs healthy controls - Retrospective data cited to argue hypothyroidism is not benign Massive observational cohorts: 1.1 million hypothyroid-treated patients vs 1.1 million healthy controls; 90,000 combination-therapy vs 90,000 levothyroxine patients - Large retrospective studies described by Bianco Desiccated thyroid ratio: roughly 3.5:1 or 4:1 T4:T3 - Linked to historic physiologic replacement studies and pig thyroid extract TSH/age adjustment: upper limit rises by about 1 point every 10 years after age 50 - Used to explain why older adults may have higher acceptable TSH values Radioactive iodine dose: about 8 to 10 millicuries - Empirical dosing range mentioned for hyperthyroidism treatment Clinical symptom ratio example: fasting shifted free T3 from 0.3 to 0.2 and reverse T3 from 10 to 35 - Used by Peter Attia to illustrate metabolic adaptation during prolonged fasting TSH example in fasting: 2 to 7 - Demonstrated how fasting can raise TSH even while lowering thyroid activity Assay variability threshold example: T3 immunoassays diverge especially around 90 to 100 ng/dL - Used to argue for mass spectrometry for T3 measurement

Pivotal Quotes: "T3 is the biologically active form. T3 is the one that..." — Dr. Antonio Bianco: Explaining why T3 measurement matters more than some clinicians acknowledge "The hypothyroidism one is not that naive disease that we thought it was. It's a deadly disease." — Dr. Antonio Bianco: Discussing mortality and systemic consequences of undertreated hypothyroidism "We need to address hypothyroidism because... these patients suffer a lot. We can't ignore that." — Dr. Antonio Bianco: Closing summary of why treatment needs to improve beyond TSH normalization

Implications: Listeners should understand that thyroid care is more nuanced than TSH alone. The field may move toward better T3 measurement, selective combination therapy, and slow-release T3, especially for patients who remain symptomatic on levothyroxine.